Mylan Statement: Generic Advair ANDA Status

October 22, 2018

In response to multiple inquiries received regarding the status of Mylan's Abbreviated New Drug Application for generic Advair® (Wixela®), Mylan confirms it has not received any new information request or complete response letter from the FDA and continues to believe that FDA approval is imminent.